As our organization grows and we are doing more and more things, there is an ever greater need for specialist knowledge and guidance to help inform our decisions as a company. We rely on the advice and expertise of both our scientific and business advisors and we have added to them this week with two new experts joining us.
We are delighted to announce that Steven A. Garan has joined our scientific advisory board. Steven is the Director of Bioinformatics at the Center for Research & Education on Aging (CREA) and serves on its advisory board, and he is a researcher at the Lawrence Berkeley National Laboratory. While at the University of California, Berkeley, he played a major role in the invention and the development of the Automated Imaging Microscope System (AIMS), and he collaborated for many years with a group from Paola S. Timiras’ lab, researching the role that caloric restriction plays in maintaining estrogen receptor-alpha and IGH-1 receptor immunoreactivity in various nuclei of the mouse hypothalamus.
Steven was also the director of the Aging Research Center and is a leading scientist in the field of aging research. His numerous publications include articles on systems biology, the effects of caloric restriction on the mouse hypothalamus, and the AIMS. He is best known for coining the word “Phenomics”, which was defined in “Phenomics: a new direction for the study of neuroendocrine aging”, an abstract published in the journal Experimental Gerontology.
We are also pleased to announce that Michael Kope has joined our industry advisory board and will support us with business expertise and guidance. Mike is the CEO and co-founder of the SENS Research Foundation, and he received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel, as Director of Corporate Development for Aviron and for MedImmune, Inc., and as CEO and officer of a number of start-ups in the biotechnology space.
He specializes in business development and consulting and is widely experienced with biotechnology organizations. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.